These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 37824026)
1. Anti-coagulant Treatment of Cancer-Associated Thrombosis in Frail Patients: Impact of Frailties on the Management of Drug-Drug Interactions. Grange C; Rioufol C; Souquet PJ; Assaad S Clin Pharmacokinet; 2023 Nov; 62(11):1523-1531. PubMed ID: 37824026 [TBL] [Abstract][Full Text] [Related]
2. Comment on: Anti-Coagulant Treatment of Cancer-Associated Thrombosis in Frail Patients: Impact of Frailties on the Management of Drug-Drug Interactions. Van der Linden L; Vanassche T; Van Aelst L; Verhamme P Clin Pharmacokinet; 2024 Mar; 63(3):395-396. PubMed ID: 38236563 [No Abstract] [Full Text] [Related]
3. An update on the efficacy and safety of novel anticoagulants for cancer associated thrombosis. Cosmi B Expert Opin Pharmacother; 2021 Apr; 22(5):583-594. PubMed ID: 33243038 [No Abstract] [Full Text] [Related]
5. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient). Pernod G; Joly M; Sonnet B J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939 [TBL] [Abstract][Full Text] [Related]
6. Complexity and clinical significance of drug-drug interactions (DDIs) in oncology: challenging issues in the care of patients regarding cancer-associated thrombosis (CAT). Tsoukalas N; Brito-Dellan N; Font C; Butler T; Rojas-Hernandez CM; Butler T; Escalante C; Support Care Cancer; 2022 Oct; 30(10):8559-8573. PubMed ID: 35932318 [TBL] [Abstract][Full Text] [Related]
7. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657 [TBL] [Abstract][Full Text] [Related]
8. Long-term treatment of cancer-associated thrombosis: the choice of the optimal anticoagulant. Elalamy I; Mahé I; Ageno W; Meyer G J Thromb Haemost; 2017 May; 15(5):848-857. PubMed ID: 28222250 [TBL] [Abstract][Full Text] [Related]
10. Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society. Milani A; Tuninetti V; Pignata S; Lorusso D; Castaldo D; De Giorgi U; Savarese A; Biglia N; Scandurra G; Mangili G; Di Maio M; Turinetto M; Bellero M; Mammoliti S; Testa S; Scotto G; Purro A; Artioli G; Valabrega G Tumori; 2023 Oct; 109(5):490-495. PubMed ID: 36609207 [TBL] [Abstract][Full Text] [Related]
11. Assessment of venous thromboembolism treatment in patients with cancer on low molecular weight heparin, warfarin, and the direct oral anticoagulants. Uppuluri EM; Burke KR; Haaf CM; Shapiro NL J Oncol Pharm Pract; 2019 Mar; 25(2):261-268. PubMed ID: 28942721 [TBL] [Abstract][Full Text] [Related]
12. Retrospective Review of Prescribing Patterns in Cancer-Associated Thrombosis: A Single Center Experience in Edmonton, Alberta, Canada. Kaliel H; Mior M; Quan S; Ghosh S; Wu C; Bungard TJ Clin Appl Thromb Hemost; 2021; 27():1076029620975489. PubMed ID: 33443455 [TBL] [Abstract][Full Text] [Related]
13. Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis. Rossel A; Robert-Ebadi H; Combescure C; Grosgurin O; Stirnemann J; Addeo A; Garin N; Agoritsas T; Reny JL; Marti C PLoS One; 2019; 14(3):e0213940. PubMed ID: 30897142 [TBL] [Abstract][Full Text] [Related]
14. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. O'Connell C; Escalante CP; Goldhaber SZ; McBane R; Connors JM; Raskob GE Oncologist; 2021 Jan; 26(1):e8-e16. PubMed ID: 33275319 [TBL] [Abstract][Full Text] [Related]
15. Direct Oral Anticoagulant for the Treatment of VTE in Cancer Patients: A Systematic Review and Meta-analysis. Dong S; Zhang Y; Li Y; Li Y; Miao Y; Zhao R; Zhai S Ann Pharmacother; 2021 Apr; 55(4):430-439. PubMed ID: 32938202 [TBL] [Abstract][Full Text] [Related]
16. How I treat and prevent venous thrombotic complications in patients with lymphoma. Schmidt RA; Lee AYY Blood; 2022 Mar; 139(10):1489-1500. PubMed ID: 34479364 [TBL] [Abstract][Full Text] [Related]
17. The Role of Direct Oral Anticoagulants in Cancer-Associated Thrombosis According to the Current Literature. Nana P; Dakis K; Peroulis M; Rousas N; Spanos K; Kouvelos G; Arnaoutoglou E; Matsagkas M Medicina (Kaunas); 2021 Sep; 57(9):. PubMed ID: 34577883 [TBL] [Abstract][Full Text] [Related]
18. Anticoagulant medication adherence for cancer-associated thrombosis: A comparison of LMWH to DOACs. Schaefer JK; Li M; Wu Z; Basu T; Dorsch MP; Barnes GD; Carrier M; Griggs JJ; Sood SL J Thromb Haemost; 2021 Jan; 19(1):212-220. PubMed ID: 33104289 [TBL] [Abstract][Full Text] [Related]
19. Current Management of Cancer-associated Venous Thromboembolism: Focus on Direct Oral Anticoagulants. Kim SA; Yhim HY; Bang SM J Korean Med Sci; 2019 Feb; 34(6):e52. PubMed ID: 30787683 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences. Bellesoeur A; Thomas-Schoemann A; Allard M; Smadja D; Vidal M; Alexandre J; Goldwasser F; Blanchet B Crit Rev Oncol Hematol; 2018 Sep; 129():102-112. PubMed ID: 30097228 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]